Palbociclib induced macrocytosis may serve as a biochemical surrogate for improved outcomes in HR+ MBC...
Our study assessing the same has been selected for presentation at ESMO breast , Berlin 2026 @myESMO@MVRCancerCentre@oncologistindia
Presenting 2 posters at @ASCO 2025.
1. Long term toxicities of Imatinib in CML
2. Real world use patterns and survival outcomes of Egfr mutated NSCLC @MVRCancerCentre
@tuttsakhil@ESMO_Open@OncoAlert We would like to inform you that your post has been published on https://t.co/igx4msDtQG. Thank you for sharing! https://t.co/S4fhcM6nQy
Happened to raise some critical points regarding the "final overall survival results of checkmate 067" in today's edition of @NEJM .Happy that the authors have responded
Interesting observations from the "KATHERINE" updated analysis results in @nejm
1. The initial IDFS benefit at 3 yrs has translated into an absolute 4.7% benefit in overall survival in favour of TDM1 Benefit irrespective of T and N stage, use of single or dual anti her 2 therapy.
@santhoshak23220 @JTOonline Happy Holidays from OncoDaily! Your post has been featured on our platforms. Thank you for sharing.
https://t.co/SKahot6jLi